NUVL

Nuvalent Class A (NUVL)

About Nuvalent Class A (NUVL)

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Details

Daily high

$83.84

Daily low

$81.88

Price at open

$83.64

52 Week High

$113.51

52 Week Low

$61.80

Market cap

5.8B

Dividend yield

0.00%

Volume

774,619

Avg. volume

577,924

P/E ratio

-23.64

Nuvalent Class A News